Mirvetuximab Soravtansine: A New Standard of Care in Ovarian Cancer?
The response rate observed with mirvetuximab soravtansine was nearly triple the benchmark set in prior studies.
Ovarian Cancer
MAPK Mutations Linked to Better PFS, OS in Low-Grade Serous Ovarian Carcinoma
The median overall survival was 147.8 months for patients with MAPK-mutated tumors and 89.5 months for patients without MAPK mutations.
Is First-Line Maintenance Underused in Advanced Ovarian Cancer?
In a study of more than 5000 patients with advanced ovarian cancer, 56% received first-line maintenance therapy.
Intraperitoneal Carboplatin Prolongs PFS After Surgery in Ovarian Cancer
Intraperitoneal carboplatin can prolong progression-free survival, but not overall survival, in patients with ovarian cancer.
Olaparib Did Not Improve PFS2, OS in SOLO3 Trial
Olaparib did improve the time to subsequent treatment and time to discontinuation or death.
Tool Predicts Need for Blood Transfusion Due to Ovarian Cancer Surgery
The tool, called the “BLOODS score,” was developed to help identify patients who may benefit from preoperative planning and blood-saving techniques.
Adjuvant Chemo May Not Improve OS in Low-Grade Serous Ovarian Carcinoma
The 4-year overall survival rate was similar with adjuvant chemotherapy and without it.
Lower-Extremity Lymphedema Common in Older, Female Cancer Survivors
Lower-extremity lymphedema is tied to lower physical functioning and a need for help with activities of daily living.
Metformin May Improve Survival in Women With Diabetes and Hormone-Related Cancers
Researchers evaluated the association between metformin and survival in women with type 2 diabetes and 3 hormone-related cancers — breast, ovarian, and endometrial cancer.
WRITE Tool Improves Symptom Management in Ovarian Cancer
Patients who used the tool under their own direction or under nurse direction had better symptom control than did patients treated with enhanced usual care.
- Loading...
Loading...
Next post in Gynecologic Cancer
Loading... 
Loading...